Latest Safety News

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

European Lithium Limited has clarified its mineral resource estimates and production targets for the Tanbreez Project following an ASX compliance query, reaffirming its basis for financial forecasts despite cautionary geological statements.

Select Harvests Limited reported a robust half-year FY2025 profit, driven by a 37.6% jump in almond prices and strategic debt refinancing. Despite a slightly reduced crop volume, the company’s outlook remains positive amid strong global demand.

Green360 Technologies has developed a proprietary low-carbon cement blend using red mud and kaolin, achieving significant reductions in hazardous leachates and competitive strength performance. The company is poised to begin commercial-scale validation with JV partner PERMAcast.

Select Harvests Limited has reported a remarkable turnaround with a $28.7 million profit in the first half of FY2025, buoyed by higher almond prices and improved operational efficiency. The company also secured $240 million in refinancing, positioning itself for future growth despite a slightly reduced almond crop forecast.

Select Harvests Limited has reported a remarkable turnaround with a $28.7 million net profit for the half-year ended March 2025, driven by higher almond prices and operational gains. The company forecasts a solid 2025 crop and has renewed a $240 million syndicated debt facility.

Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Champion Iron Limited reported record quarterly sales and strong earnings in FY2025 Q4, while advancing its DRPF project on schedule and declaring its eighth consecutive dividend.

HITIQ has secured a three-year deal with AFL Barwon to promote its PROTEQT smart mouthguard across regional Victoria, enhancing concussion management in community sports.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.